The new drug has already passed Phase 1 safety trials in humans, making it a "strong candidate" for future PTSD treatments.

Researchers discovered that PTSD may be driven by excess GABA from astrocytes, not neurons. This chemical imbalance disrupts ...

Excessive levels of GABA released by astrocytes impair the brain's ability to extinguish fear responses in PTSD, but a newly ...

Did you know that patients with post traumatic stress disorder (PTSD) often struggle to forget traumatic memories, even long ...

GABA Receptor Agonist Market Research report comprises of a brief summary on the trends and tendency that may help the key market players functioning in the industry to understand the market and ...

GABA receptor agonist market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the ...

Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator Company Expects to File U.S. IND Applications in 2021 for PDE4B and Kappa Opioid ...